HealthShares Announces Changes To Infectious Disease Indexes
Companies included in the Infectious Disease Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of infectious diseases.
Solvay SA will replace Medimmune in the HealthShares Infectious Disease Index, UCB will replace Medimmune in the HealthShares Respiratory/Pulmonary Index, and Fresenius will replace Medimmune in the HealthShares Cancer Index and the HealthShares Composite Index. Medimmune is being acquired by U.K. based AstraZeneca PLC.
Companies included in the Respiratory/Pulmonary Index are engaged in the research, development, and/or commercialization of therapeutic agents treating various respiratory and/or pulmonary diseases including, but not limited to, asthma, chronic obstructive pulmonary disease, emphysema, tuberculosis and pulmonary arterial hypertension.
Companies included in the Cancer Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of cancers. Companies in this index generally include those with substantial revenues and significant research and development programs.
There are risks involved with investing in ETFs including possible loss of money. HealthShares are not actively managed and are subject to risks similar to stocks, including those related to short selling and margin maintenance. Losses from short sales may be unlimited, and losses from purchases on margin may exceed original investment. HealthShares ETFs are subject to increased risks associated with investing in a specific sector compared to a more diversified investment, as well as unique risks associated with the healthcare and biotechnology sector (i.e., government regulation, patent regulation, etc.).
The ETFs face additional risks attributable to their investments in small and medium capitalization companies which are subject to higher volatility than larger, more established companies. In addition, they are invested in a limited number of securities and a decline in the value of these investments would cause the fund's overall value to decline to a greater degree than in a less concentrated portfolio.
Global or International Funds invest in foreign securities that may be subject to certain risks not associated with domestic securities, such as currency fluctuations, and changes in political and economic conditions.
The prospectus is not an offer to buy or sell the portfolio shares, nor is the fund soliciting an offer to buy its shares in any jurisdiction where the offer or sale is not permitted.